Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 4668  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (2,605 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

  In this Article
 »  Abstract
 »  Materials and Me...
 » Results
 » Discussion
 » Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    PDF Downloaded82    
    Comments [Add]    

Recommend this journal


Table of Contents    
Year : 2020  |  Volume : 68  |  Issue : 7  |  Page : 146-153

Hypothalamic Hamartoma and Endocrinopathy: A Neurosurgeon's Perspective

1 Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
2 Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
3 Department of Neurosurgery, Netaji Subhash Chandra Bose Medical College, Jabalpur, Madhya Pradesh, India
4 Department of Neurosurgery, MS Ramaiah Medical College and Hospital, Bengaluru, Karnataka, India
5 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
6 Department of Neuroradiology, All India Institute of Medical Sciences, New Delhi, India

Date of Web Publication24-Jun-2020

Correspondence Address:
Dr. P Sarat Chandra
Professor, Department of Neurosurgery, PI and Team Leader COE Epilepsy and MEG Center, All India Institute of Medical Sciences, New Delhi - 110 029
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.287681

Rights and Permissions

 » Abstract 

Background: The management of hypothalamic hamartomas (HH) rests upon the type of presentation. These are rare congenital benign lesions presenting either with central precocious puberty (CPP), drug refractory epilepsy (DRE) or combination of both. We present here our experience in the management of these lesions from a neurosurgeon's perspective and review the pertinent literature.
Objective: To present a series of HH presenting with CPP and DRE managed in the neurosurgery department at our center with an emphasis on the associated endocrine abnormalities.
Materials and Methods: A prospective observational study over a period of five years included 16 patients of HH. All patients were evaluated with 3 Tesla Magnetic Resonance Imaging (MRI) brain, complete hormonal workup including gonadotrophins, testosterone (males) and estradiol (females), and video-electroencephalography (VEEG) as a part of epilepsy workup. All these patients were evaluated with postoperative hormonal workup and repeat MRI brain if repeat surgery was contemplated.
Results: Among the 16 patients of HH, there were 11 male and 6 female children. All the patients presented with DRE with four of these had associated CPP. All the patients underwent robotic-guided radiofrequency ablation (RFA), with 75% seizure freedom following 1st RFA surgery. Three of the four patients with CPP achieved both clinical and biochemical normalization. One patient had just a marginal reduction in the serum gonadotrophins. One patient was reoperated twice and three underwent RFA thrice.
Conclusion: The management of HH should be individualized with DRE taking the precedence requiring early surgery. A multidisciplinary approach is therefore recommended for a successful outcome.

Keywords: Central precocious puberty, drug-refractory epilepsy, gelastic seizures, gonadotrophins, radiofrequency ablation, robot
Key Message: The presentation depends upon the anatomical location of HH. Those arising near the infundibulum produce CPP (group-1), those in the vicinity of mammillary body presenting with DRE (group-2) and large lesions spanning the 3rd ventricular floor from mammillary body to the infundibulum area give rise to a combination of features (group-3). The group-2 and 3 patients primarily require neurosurgical management. Robotic-guided RFA offers a minimally invasive surgery with excellent outcomes with regards to both CPP and epilepsy.

How to cite this article:
Doddamani RS, Tripathi M, Samala R, Agrawal M, Ramanujam B, Bajaj J, Girishan S, Tripathi M, Bal C S, Garg A, Chandra P S. Hypothalamic Hamartoma and Endocrinopathy: A Neurosurgeon's Perspective. Neurol India 2020;68, Suppl S1:146-53

How to cite this URL:
Doddamani RS, Tripathi M, Samala R, Agrawal M, Ramanujam B, Bajaj J, Girishan S, Tripathi M, Bal C S, Garg A, Chandra P S. Hypothalamic Hamartoma and Endocrinopathy: A Neurosurgeon's Perspective. Neurol India [serial online] 2020 [cited 2021 Mar 7];68, Suppl S1:146-53. Available from:

Hypothalamic hamartomas (HH) are rare developmental malformations often arising from the floor of the hypothalamus involving either tuber cinereum or mammillary bodies. These lesions occur most often sporadically and occasionally as a part of Pallister–Hall Syndrome (PHS) in approximately 10% of cases. The incidence of HH in the literature as per the Swedish study is 0.0005% with a slight male predominance.[1] Another population-based study from Israel documented an incidence of one per 6, 25, 000 cases.[2] HH express themselves, either featuring with central precocious puberty (CPP) in 1/3rd, drug refractory epilepsy (DRE) in up to 40%, or a mixture of both in the remaining 1/3rd patients.[3] Historically, the management of HH irrespective of its presentation was solely limited to surgical excision. However, with the advent of gonadotrophin-releasing hormone (GnRH) analogs, medical management currently forms the most effective therapy with excellent results in HH patients presenting exclusively with CPP. Apart from CPP, these lesions also present with multiple seizure types with the gelastic semiology being characteristic. Nearly all the patients suffering from epilepsy are resistant to medication; hence, surgery offers the only chance of cure in this subset of patients. Therefore, approximately 2/3rd patients of HH suffering from CPP and DRE, either in combination or DRE alone, require neurosurgical care.[3],[4],[5],[6]


  1. We present here our experience in the management of these lesions presenting with CPP and DRE
  2. To also present a review of the endocrinological aspects of HH and its management.

 » Materials and Methods Top

A prospective observational study including 16 patients diagnosed with HH, managed at our institute in the neurosurgery department, over a period of 5 years (2014-2019). All these patients were evaluated with 3 Tesla magnetic resonance imaging (MRI) brain, a complete hormonal workup, and video electro-encephalography (VEEG) as a part of the evaluation for epilepsy. Most often, these investigations were sufficient for the diagnosis and management of HH. The hamartomas were classified as per Delalande's grading system, based on the MRI of the brain. Positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) were rarely performed, especially in cases with a diagnostic dilemma related to epilepsy. The hormonal workup was performed both in the pre and postoperative periods. The outcomes in terms of seizure freedom, requirement for hormone supplementation, and complications were recorded during the follow-up at regular intervals. All the data were retrieved from the case files, computerized patient record system (CPRS), and picture archiving and communication systems (PACS) and are shown in [Table 1].
Table 1: Demographic and clinical data

Click here to view


The MRI images are transferred from the PACS into the ROSA platform and multiple trajectories and lesion points are planned a day prior to the surgery. The lesions are so planned that the hamartoma is effectively disconnected from the hypothalamic attachment and also to ablate the hamartomatous tissue to the maximal possible extent [Figure 1].
Figure 1: (a) The OR setup showing the patient in supine position and head fixed with Mayfields clamp attached to the robotic lever (ROSA) with its monitor following registration. “O”arm in position for intraoperative spin which helps in confirmation of the position of the RF probe, prior to proceeding with the ablation. (b and f) displaying the planned trajectories on the ROSA platform targeting the interphase between the normal hypothalamus and the hamartoma. (c and d) Leksell pulse generator and the RF probe, respectively, where the temperature is set at 74 °C for 60 s. (e) The RF probe inserted into the preplanned trajectory through a twist drill hole created using 2.5 mm drill bit guided by the robotic arm, awaiting O-arm confirmation before ablation begins

Click here to view

Surgical technique

All the patients underwent robotic-guided radiofrequency ablation (RFA) of the hamartoma, a technique already described from our institution.[7] The prerequisites for performing the procedure are [Figure 1]:

  1. ROSA robotic machine (Zimmer Biomet Warsaw, Indiana).
  2. A 3 Tesla T1WI, T2WI, fluid-attenuated inversion recovery (FLAIR) and Gadolinium-enhanced MRI brain acquired in 3D sequence with 1 mm slice thickness and in a square matrix.
  3. Radio-frequency pulse generator (Leksell) for ablation.
  4. O arm for intraoperative confirmation of the position of the probe prior lesioning.

In brief, the lesioning is performed with the patient under general anesthesia. The patient is supine, head is fixed in slight flexion with Mayfield clamp. Following robotic registration, the lesioning is commenced by inserting the RFA probe, through multiple twist drill holes (2.5 mm drill bit) as per the number of planned trajectories. Once the probe is inserted to the precalculated distance by the ROSA software, an O-arm spin is performed prior performing the first lesion. The O-arm data acquired are then superimposed with the preplanned robotic trajectory to confirm the position of the probe. Once the probe position is deemed satisfactory, an “ablative disconnection” of the hamartoma is created using the radiofrequency pulse generator. We use the protocol of 74 °C temperature for 60 s to achieve the tissue ablation.

Postoperative management

All patients were monitored in the intensive care unit (ICU) rigorously for any signs of dyselectrolytemia like diabetes insipidus (DI) and syndrome of inappropriate antidiuretic hormone (SIADH). The fluid and electrolyte balance was maintained in case of any derangement by appropriate therapy. Serum hormonal levels were repeated 72 h, two weeks and one month after surgery. Repeat MRI was performed in patients with recurrence or persistence of seizures at least three months following surgery, to look for a residual connection.

 » Results Top

Among the 16 patients with HH managed at our center, there were 11 male and 5 female children. The age ranged between 7 months and 18 years, with a mean of 7.18 years. All the patients suffered from DRE and were on multiple antiepileptic drugs (AEDs). In addition, four patients suffered from CPP; one was a female and three male children. One of these male child harbored HH as a part of PHS with polysyndactyly in both the hands and feet, along with bifid epiglottis [Figure 2]. Majority of the hamartomas were: Delalande's grade-3 (n = 11), grade-4 (n = 2), and one each in grade-1 and grade-2 [Figure 3], [Figure 4], [Figure 5], [Figure 6]. Preoperative hormonal workup was abnormal in all the four patients presenting with CPP. One of the three male children was aged two years with Tanners stage-III on sexual maturity rating. This child had increased serum luteinizing hormone (LH) and FSH levels. The other two male and female children were in Tanners stage II and III, respectively, with elevated serum LH/FSH levels. The preoperative hormonal workup was within normal limits in the rest of the 12 patients [Table 1].
Figure 2: A 2-year-old male child with Delalande's type-3 HH presented with both CPP and gelastic epilepsy as a part of Pallister–Hall syndrome (PHS). (a) Note the acne over the forehead and cheek. (b and c) Syndactyly and polydactyly in both feet and hands as part of PHS. (d) Well-developed primary and secondary sexual organs along with pubic and axillary hairs, Tanners stage-3 on sexual maturity rating (6 mL volume bilateral testes)

Click here to view
Figure 3: Delalande's type -1. (a) Preoperative FLAIR MRI in axial sagittal and coronal showing a pedunculated HH in the suprasellar cistern also known as parahypothalamic hamartoma. (b) Early postoperative MRI following RFA. Note the edema within the hamartoma, visible as FLAIR hyperintensity at the interphase between the hamartoma and normal hypothalamus

Click here to view
Figure 4: Delalande's type-2. (a) Sagittal T1WI and Coronal FLAIR MRI, showing a small sessile intraventricular hamartoma. (b) Postoperative CT showing hypodensity in the region of the hamartoma representing lesioning

Click here to view
Figure 5: Delalande's type-3. (a) Contrast MRI brain coronal section showing nonenhancing lesion, isointense to the gray matter, arising from the hypothalamus with bilateral attachment, extending both into the 3rd ventricle and the suprasellar cistern. This patient achieved ILAE-1 seizure outcome following RFA. (b) T1WI coronal sections of MRI brain showing good “ablative disconnection” of the interface between hamartoma and the normal hypothalamus

Click here to view
Figure 6: Delalande's Type-4. (a) Preoperative MRI brain of a 6-year-old boy showing a giant HH, presented with CPP and gelastic seizures. (b) Post first RFA showing evidence of ablation at the interface (arrow head). This patient needed 2nd RFA for residual connection with persistent seizure and remains seizure free at 1-year follow-up

Click here to view

Postoperative outcome

Seizure outcomes

Overall 12 (75%) among 16 patients achieved ILAE Class-1 seizure outcomes, following first lesioning. Out of the four patients with persistent seizures, three were in Class-III and one patient continued to be in Class-IV, after a brief seizure-free interval. All the four patients underwent repeat RFA with one patient achieving seizure freedom and the remaining three continued to have recurrent seizures requiring a third RFA. Only two patients underwent 3rd RFA and attained Class-1 seizure freedom at the last follow-up 12 and 14 months. The remaining one patient is awaiting a 3rd RFA. The seizure outcomes achieved at the end of 3 RFAs were ILAE Class-1 in 93.75% cases with a mean follow-up of 15 months (Range: 9–36 months) [Table 2] and [Figure 7], [Figure 8].
Table 2: Seizure outcomes

Click here to view
Figure 7: Repeat RFA. A Delalande's Type-2 HH with gelastic epilepsy, relapsed following first RFA. (a) A repeat MRI at 6 months showed evidence of residual connections with the hypothalamus (arrows), with major attachment of the HH already ablated during 1st RFA (evidenced by the gliotic cavity). (b) CT brain following 2nd RFA, this patient remains seizure free at 18-month follow-up

Click here to view
Figure 8: Bar chart depicting 75% ILAE class-1 outcome following first RFA surgery. Overall, the seizure outcomes at the end of repeat RFA surgeries accounted to 93.75% with one patient with Class-3 outcome awaiting surgery

Click here to view

Endocrinological outcomes

The basal serum LH reduced significantly to the prepubertal level (<0.3 mIU/mL) in three patients and marginal decrease was noted in one patient with CPP [Table 3]. Four patients developed DI in the immediate postoperative period; two of these recovered spontaneously without any additional therapy. The remaining two patients developed permanent DI requiring regular desmopressin nasal spray. Two patients needed cortisol supplementation owing to persistent low serum cortisol in the postoperative period. One patient developed thyroid hormone deficiency following repeat surgery and hence was started on thyroxin replacement. Two patients developed postoperative weight gain of more than 5 kg within a year after surgery. No new deficits were encountered in the remaining patients [Table 2].
Table 3: Effect of surgery on serum gonadotropin levels in patients with CPP

Click here to view

Postoperative complications

Nonhormonal complications included transient visual deterioration in one patient, persistent fever of central origin without any evidence of sepsis and prolonged drowsiness was encountered in the same patient, which resolved spontaneously over a period of 1 month [Table 2].

 » Discussion Top

Hypothalamic hamartomas are benign developmental lesions comprising of dysplastic neurons, interspersed with glial tissue. The only and most common endocrine abnormality detected in these lesions is the GnRH hypersecretion at an inappropriate age. Rest of the other hormonal secretion often remains unaffected, with unusually rare exceptions where growth hormone hypersecretion is noted. Molecular studies have revealed the cell groups within these lesions are comprised of GnRH granules. It is also noted that certain cells also stain positively for some proteins like TGF-Alfa (Transforming Growth Factor) and Kiss-peptin, both responsible for pubertal growth. It is seen in normal individuals that the pulsatile secretion of GnRH ensues at the time of onset of puberty.[8],[9] This pulsatile release is the most important prerequisite for the pubertal growth in humans.[10],[11] Electrophysiological studies have shown that the hamartoma cells are intrinsically highly epileptogenic, thereby rendering these patients susceptible to DRE. These lesions, therefore, usually present either with CPP, DRE or a combination of both.[12],[13],[14]

Imaging (MRI brain) usually is sufficient for the diagnosis of HH, as these are nonprogressive lesions (on serial imaging) arising from the hypothalamus, showing up as T1 isointense to the normal gray matter without contrast enhancement. Nebulae of classification schemes for HH exist in the literature published by multiple authors. Beginning from the era of CT scans to high-resolution MRI, all these classification schemes were devised so as to address the surgical approach and also to predict the clinical presentation. The following significant observations are noted and well documented in the literature, based on the imaging findings:

  1. In patients presenting with isolated CPP, the HH originated from the tuber cinereum close to pituitary stalk or the infundibular part of the third ventricular floor. They are usually pedunculated parahypothalamic hamartomas
  2. The sessile intrahypothalamic HH within the 3rd ventricle or those located more posteriorly close to the mammillary bodies presented with gelastic seizures and DRE
  3. Large HH with broad-based attachment to the third ventricular floor can present with features of both DRE and CPP.

The above findings are frequently witnessed but not absolute and may vary with the individual patient [Figure 9].[15],[16],[17]
Figure 9: Schematic illustration depicting the diencephalon in midsagittal section. (a) Sessile hypothalamic hamartomas (HH) arising from hypothalamic floor attached to mamillary body are more prone to develop DRE. (b) Pedunculated HH arising from the 3rd ventricular floor close to the infandibulum usually present with CPP. (c) Large HH with broad attachment spanning from mamillary body till the infandibulum present with a combination of DRE and CPP. AC-Anterior Commissure; CC-Corpus Callosum; CG- Cingulate Gyrus; H-Hypothalamus; HH-Hypothalamic hamartoma; LV- Lateral Ventricle; T-Thalamus

Click here to view

Management of hypothalamic hamartomas

The management of the HH should be individualized depending upon their presentations. Hence, for the purpose of simplicity, they can be divided into 3 groups:

Group-1: Isolated CPP

Group-2: Isolated DRE

Group-3: Both DRE and CPP.

In our series, we had 75% (n = 12) patients belonging to group-2, 25% (n = 4) patients in the group-3, and none in the group-1 (as these patients are primarily referred to the endocrinology department).

Precocious puberty (PP) is defined as the development of secondary sexual characteristics prior to eight years in females and before nine years in male. PP occurring due to any intracranial lesion in the sellar/parasellar or hypothalamic involvement, which is GnRH dependent, is termed as central. Clinical evaluation of the breast development in females and testicular volume in males forms an important aspect of diagnosing PP. This is based upon the Tanners classification or sexual maturity rating. Biochemical evaluation includes complete hormonal workup including basal levels of serum leutinizing hormonal (LH)/follicle stimulating hormone (FSH). GnRH stimulation testing is also used for the diagnosis of CPP, whenever the elevation in basal level of LH is ambiguous. In the presence of HH with PP clinically, either random basal serum LH >0.3 IU/mL or a peak stimulated LH of >8 mIU/mL or 5 IU/L after GnRH or GnRH analog stimulation, respectively, are considered indicative of CPP.[10],[18]

The management of CPP is mainly medical and focuses on two most important aspects of development, namely, the attainment of final adult height and dealing with the psychosocial aspects. As the premature secretion of the sex steroids leads to premature fusion of the epiphysis, the final adult height attained becomes restricted. Therefore, it is prudent to start the therapy with GnRH analogs the earliest. The best results are obtained when the therapy is begun before six years of age. Modest results are noted between 6–8 years and no benefit if started at eight years and beyond. The other most important aspect is the psychological and the social issues the child has to deal with. These patients' outlook is that of the adults but with a lesser mental age equivalent to their peer group. Often, they are stigmatized by the peer group at school and might end up being the victims of abuse. The inability to handle menstrual hygiene and aggressive behavior in the male children are other major concerns needing attention. Hence, GnRH therapies are offered so as to slow-down and regularize the development, till the age of puberty and then withdraw once appropriate age and proper understanding is attained. This is done after detailed discussion with the parents.[10],[18]

There has been a paradigm shift in the management of patients belonging to group-1. Surgical excision of the HH was the only treatment option available in the past. The development of effective GnRH analogs over the past 50 years, following the discovery of the gonadotropins structure in 1971, has revolutionized the treatment of CPP.[19] Nevertheless, there have been few reports in the literature offering surgical excision both in pre and post GnRH era. Although good clinical and biochemical outcomes have been demonstrated, the data are limited to a few case reports and short series.[20],[21],[22],[23],[24],[25] Currently, the availability of long-acting GnRH analogs like leuprolide (7.5 / 11.25 mg) and triptorelin (7.5 / 11.25 mg), which can be administered as 1 or 3 monthly depot intramuscular injections, respectively, offer a convenient mode of therapy.[26],[27] Similarly, GnRH nasal sprays (Busarelin/Nefarelin) have made the therapy more acceptable, avoiding the need for repeated injections.[28]

In this era of best available medical therapy, subjecting a patient to invasive surgery and its complications seems inappropriate for isolated CPP.[23] As CPP represents a normal physiological phenomenon, beginning at an inappropriately early developmental stage, postponing the process till appropriate age with GnRh analogs offers a more logical solution.

The group-2 patients present with the characteristic gelastic (laughing episodes) seizures, which is the predominant seizure type witnessed in patients with HH. Dacrystic (crying episodes) and rarely focal or generalized seizures types are other forms of epilepsy associated with HH. These patients are to be managed in a specialized neurosurgical setup with experience in managing DRE, as surgery offers the only chance of cure. The surgical approach for HH has evolved with time from open surgical resection to endoscopic transcallosal-transventricular disconnection. Stereotactic “ablative disconnection” using laser and RFA of the HH are the latest modalities with excellent seizure-free outcomes with minimal morbidity.[7],[25],[29],[30],[31],[32],[33],[34],[35],[36],[37] Kameyama et al. have reported the largest single center experience (n = 150) of ablative disconnection using RFT. They reported overall 71.3% International League Against Epilepsy (ILAE) Class-1 seizure outcomes, without any mortality or permanent morbidity, following first RFA.[38]

In our experience, overall 12 (75%) among 16 patients achieved ILAE Class-1 seizure outcomes, following first lesioning. Repeat surgeries were performed in four patients with persistent seizures with evidence of residual connection on the MRI. Class-1 ILAE outcome was attained in 93.75% patient at the end of two repeat surgery in one and three times in two patients. One patient still awaits a repeat surgery following two failed attempts [Figure 8].

The group-3 patients require a well-coordinated, multispecialty team management involving the neurosurgeon, neurologist, and endocrinologist. Early seizure control takes the precedence, as these patients continue to worsen progressively in the psychosocial intelligence and irreversible brain damage, leading to severe epileptic encephalopathy if left untreated. This along with the appropriate endocrinological management, as already outlined for the group-1 and 2 patients leads to a successful outcome.[10],[18],[39]

We encountered four patients with DRE and CPP accounting for 25% of the total cases. Two of these patients had giant HH (Delalande's type-IV). All the 4 lesions had a broad attachment to the 3rd ventricular floor, as noted in the midsagittal section of MRI brain. Following stereotactic RFA, three patients had the serum LH returned to the prepubertal level and one patient had marginal reduction in the serum LH. Only one patient required repeat RFA for persistent seizures.

 » Conclusion Top

Hypothalamic hamartomas are rare congenital lesions presenting with endocrinopathy, drug-refractory epilepsy, or a combination of both. The location of the HH in relation to the 3rd ventricular floor determines their presentation. A multidisciplinary approach involving neurophysicians, neurosurgeons, and endocrinologist yields best results. Isolated CPP is best managed medically under the care of an endocrinologist. Early seizure control should be the goal in all cases with drug-refractory epilepsy and promptly referred to specialized epilepsy center.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

This study has been partly supported by Center of Excellence For Epilepsy (COE-E), funded by Dept of Biotechnology, Ministry of Science and Technology, India.

Conflicts of interest

There are no conflicts of interest.

 » References Top

Brandberg G, Rainmaker R, Eeg-Ollfsson O. Hypothalamic hamartoma with gelastic seizures in sewdish children and adolescents. Eur J Pediatr Neurol 2004;8:35-44.  Back to cited text no. 1
Shahar E, Kramer U, Mahajnah M, Lerman-Sagie T, Goez R, Gross VJ, et al. Pediatric onset gelastic seizures: Clinical data and outcome. Pediatr Neurol 2007;37:29-34.  Back to cited text no. 2
Li CD, Luo SQ, Tang J, Jia G, Ma ZY, Zhang YQ. Classification of hypothalamic hamartoma and prognostic factors for surgical outcome. Acta Neurol Scand 2014;130:18-26.  Back to cited text no. 3
Nguyen D, Singh S, Zaatreh M, Novotny E, Levy S, Testa F, et al. Hypothalamic hamartomas: Seven cases and review of the literature. Epilepsy Behav 2003;4:246-58.  Back to cited text no. 4
Cukier P, Castro LH, Banaskiwitz N, Teles LR, Ferreira LR, Adda CC, et al. The benign spectrum of hypothalamic hamartomas: Infrequent epilepsy and normal cognition in patients presenting with central precocious puberty. Seizure 2013;22:28-32.  Back to cited text no. 5
Parvizi J, Le S, Foster BL, Bourgeois B, Riviello JJ, Prenger E, et al. Gelastic epilepsy and hypothalamic hamartomas: Neuroanatomical analysis of brain lesions in 100 patients. Brain 2011;134:2960-8.  Back to cited text no. 6
Tandon V, Chandra PS, Doddamani RS, Subianto H, Bajaj J, Garg A, et al. Stereotactic radiofrequency thermocoagulation of hypothalamic hamartoma using robotic guidance (ROSA) coregistered with O-arm guidance-preliminary technical note. World Neurosurg 2018;112:267-74.  Back to cited text no. 7
Jung H, Carmel P, Schwartz MS, Witkin JW, Bentele KH, Westphal M, et al. Some hypothalamic hamartomas contain transforming growth factor alpha, a puberty-inducing growth factor, but not luteinizing hormone-releasing hormone neurons. J Clin Endocrinol Metab 1999;84:4695-701.  Back to cited text no. 8
Chan YM, Fenoglio-Simeone KA, Paraschos S, Muhammad L, Troester MM, Ng YT, et al. Central precocious puberty due to hypothalamic hamartomas correlates with anatomic features but not with expression of GnRH, TGFalpha, or KISS1. Horm Res Paediatr 2010;73:312-9.  Back to cited text no. 9
Chen M, Eugster EA. Central precocious puberty: Update on diagnosis and treatment. Paediatr Drugs 2015;17:273-81.  Back to cited text no. 10
Harrison VS, Oatman O, Kerrigan JF. Hypothalamic hamartoma with epilepsy: Review of endocrine comorbidity. Epilepsia 2017;58(Suppl 2):50-9.  Back to cited text no. 11
Wu J, Gao M, Shen JX, Qiu SF, Kerrigan JF. Mechanisms of intrinsic epileptogenesis in human gelastic seizures with hypothalamic hamartoma. CNS Neurosci Ther 2015;21:104-11.  Back to cited text no. 12
Kerrigan JF, Parsons A, Tsang C, Simeone K, Coons S, Wu J. Hypothalamic hamartoma: Neuropathology and epileptogenesis. Epilepsia 2017;58(Suppl 2):22-31.  Back to cited text no. 13
Freeman JL, Zacharin M, Rosenfeld JV, Harvey AS. The endocrinology of hypothalamic hamartoma surgery for intractable epilepsy. Epileptic Disord 2003;5:239-47.  Back to cited text no. 14
Debeneix C, Bourgeois M, Trivin C, Sainte-Rose C, Brauner R. Hypothalamic hamartoma: Comparison of clinical presentation and magnetic resonance images. Horm Res 2001;56:12-18.  Back to cited text no. 15
Freeman JL, Coleman LT, Wellard RM, Kean MJ, Rosenfeld JV, Jackson GD, et al. MR imaging and spectroscopic study of epileptogenic hypothalamic hamartomas: Analysis of 72 cases. AJNR Am J Neuroradiol 2004;25:450-62.  Back to cited text no. 16
Jung H, Neumaier Probst E, Hauffa BP, Partsch CJ, Dammann O. Association of morphological characteristics with precocious puberty and/or gelastic seizures in hypothalamic hamartoma. J Clin Endocrinol Metab 2003;88:4590-5.  Back to cited text no. 17
Fuqua JS. Treatment and outcomes of precocious puberty: An update. J Clin Endocrinol Metab 2013;98:2198-207.  Back to cited text no. 18
Eugster EA. Treatment of central precocious puberty. J Endocr Soc 2019;3:965-72.  Back to cited text no. 19
Luo S, Li C, Ma Z, Zhang Y, Jia G, Cheng Y. Microsurgical treatment for hypothalamic hamartoma in children with precocious puberty. Surg Neurol 2002;57:356-62.  Back to cited text no. 20
Albright AL, Lee PA. Neurosurgical treatment of hypothalamic hamartomas causing precocious puberty. J Neurosurg 1993;78:77-82.  Back to cited text no. 21
Stewart L, Steinbok P, Daaboul J. Role of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty. Report of six cases. J Neurosurg 1998;88:340-5.  Back to cited text no. 22
Ghanta RK, Koti K, Kongara S, Meher GE. Surgical excision of hypothalamic hamartoma in a twenty months old boy with precocious puberty. Indian J Endocrinol Metab 2011;15(Suppl 3):S255-8.  Back to cited text no. 23
Li CD, Luo SQ, Gong J, Ma ZY, Jia G, Zhang YQ, et al. Surgical treatment of hypothalamic hamartoma causing central precocious puberty: Long-term follow-up. J Neurosurg Pediatr 2013;12:151-4.  Back to cited text no. 24
Deopujari CE, Suhas U. Surgical considerations in the management of gelastic seizures. J Pediatric Neurosci 2008;3:88-93.  Back to cited text no. 25
Lee PA, Klein K, Mauras N, Lev-Vaisler T, Bacher P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab 2014;99:3153-9.  Back to cited text no. 26
Durand A, Tauber M, Patel B, Dutailly P. Meta-analysis of paediatric patients with central precocious puberty treated with intramuscular triptorelin 11.25 mg 3-month prolonged-release formulation. Horm Res Paediatr 2017;87:224-32.  Back to cited text no. 27
Tuvemo T, Gustafsson J, Proos LA; Swedish Growth Hormone Group. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist. Horm Res 2002;57:27-31.  Back to cited text no. 28
Palmini A, Chandler C, Andermann F, Costa Da Costa J, Paglioli-Neto E, Polkey C, et al. Resection of the lesion in patients with hypothalamic hamartomas and catastrophic epilepsy. Neurology 2002;58:1338-47.  Back to cited text no. 29
Jayalakshmi S, Vooturi S, Gupta S, Panigrahi M. Epilepsy surgery in children. Neurol India 2017;65:485-92.  Back to cited text no. 30
[PUBMED]  [Full text]  
Ng YT, Rekate HL, Prenger EC, Chung SS, Feiz-Erfan I, Wang NC, et al. Transcallosal resection of hypothalamic hamartoma for intractable epilepsy. Epilepsia 2006;47:1192-202.  Back to cited text no. 31
Rekate HL, Feiz-Erfan I, Ng YT, Gonzalez LF, Kerrigan JF. Endoscopic surgery for hypothalamic hamartomas causing medically refractory gelastic epilepsy. Childs Nerv Syst 2006;22:874-80.  Back to cited text no. 32
Chandra SP, Tripathi M. Endoscopic epilepsy surgery: Emergence of a new procedure. Neurol India 2015;63:571-82.  Back to cited text no. 33
[PUBMED]  [Full text]  
Ng YT, Rekate HL, Prenger EC, Wang NC, Chung SS, Feiz-Erfan I, et al. Endoscopic resection of hypothalamic hamartomas for refractory symptomatic epilepsy. Neurology 2008;70:1543-8.  Back to cited text no. 34
Kuzniecky RI, Guthrie BL. Stereotactic surgical approach to hypothalamic hamartomas. Epileptic Disord 2003;5:275-80.  Back to cited text no. 35
Du VX, Gandhi SV, Rekate HL, Mehta AD. Laser interstitial thermal therapy: A first line treatment for seizures due to hypothalamic hamartoma? Epilepsia 2017;58(Suppl 2):77-84.  Back to cited text no. 36
Kameyama S, Murakami H, Masuda H, Sugiyama I. Minimally invasive magnetic resonance imaging-guided stereotactic radiofrequency thermocoagulation for epileptogenic hypothalamic hamartomas. Neurosurgery 2009;65:438-49; discussion 449.  Back to cited text no. 37
Shirozu H, Masuda H, Kameyama S. Repeat stereotactic radiofrequency thermocoagulation in patients with hypothalamic hamartoma and seizure recurrence. Epilepsia Open 2020;5:107-20.  Back to cited text no. 38
Kim H, Kim J, Kim MS, Lee DY, Kim SJ. Central precocious puberty in children with devastating brain damage: Two cases. Neurol India 2016;64:1047-8.  Back to cited text no. 39
[PUBMED]  [Full text]  


  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9]

  [Table 1], [Table 2], [Table 3]


Print this article  Email this article
Online since 20th March '04
Published by Wolters Kluwer - Medknow